Pàgina inicial > Resultats de la cerca: Thrombotic microangiopathy
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
13 p, 1.2 MB Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy : A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research / Schoettler, M.L. (Children's Healthcare of Atlanta) ; Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cho, Byung-Sik (The Catholic University of Korea) ; Dandoy, Christopher E. (Cincinnati Children's Hospital Medical Center) ; Ho, Vincent Trien Vinh (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ; Jodele, Sonata (Cincinnati Children's Hospital Medical Center) ; Moissev, I. (Pavlov First Saint Petersburg State Medical University) ; Sańchez Ortega, Isabel (European Society for Bone Marrow Transplant) ; Srivastava, Alok (Christian Medical College Vellore) ; Atsuta, Yoshiko (Aichi Medical University) ; Carpenter, Paul A. (Seattle Children's Hospital) ; Koreth, John (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ; Kröger, Nicolaus M. (Ohio State. University) ; Ljungman, Per (Karolinska Institutet (Estocolm, Suècia)) ; Page, Kristin M. (Medical College of Wisconsin) ; Popat, Uday R. (The University of Texas MD Anderson Cancer Center) ; Shaw, Bronwen E. (Medical College of Wisconsin) ; Sureda Balari, Anna Maria (Institut Catala d'Oncologia-Hospital Duran i Reynals) ; Soiffer, Robert J. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ; Vasu, Sumithira V. (Ohio State. University)
Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic cell transplantation (HCT) associated with significant morbidity and mortality. [...]
2023 - 10.1016/j.jtct.2022.11.015
Transplantation and Cellular Therapy, Vol. 29 Núm. 3 (march 2023) , p. 151-163  
Registre complet - Creative Commons
2.
13 p, 1.8 MB The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment / Ariceta Iraola, Gema (Hospital Universitari Vall d'Hebron) ; Dixon, B.P. (Renal Section. Department of Pediatrics. University of Colorado School of Medicine) ; Kim, S.H. (Department of Pediatrics. Pusan National University Children's Hospital) ; Kapur, G. (Faculty of Pediatric Sciences. Central Michigan University. Mount Pleasant) ; Mauch, T. (Department of Nephrology and Hypertension. Division of Pediatrics. University of Utah) ; Ortiz, S. (Clinical and Non-Clinical Pharmacology. Alexion Pharmaceuticals Inc.) ; Vallee, M. (Biostatistics. Alexion Pharmaceuticals Inc.) ; Denker, A.E. (Clinical Development. Alexion Pharmaceuticals Inc.) ; Kang, H.G. (Division of Pediatric Nephrology. Department of Pediatrics. Seoul National University College of Medicine) ; Greenbaum, L.A. (Division of Pediatric Nephrology. Emory University School of Medicine and Children's Healthcare of Atlanta) ; Lovell, H. ; Muff-Luett, M. ; Malone, K. ; Adeagbo, O. ; Wilkerson, A. ; Fraga Rodríguez, Gloria María (Institut d'Investigació Biomèdica Sant Pau) ; Sarri, S. ; Cheong, H.I. ; Ahn, Y.H. ; Han, K.H.
Ravulizumab, a long-acting complement C5 inhibitor engineered from eculizumab, allows extending maintenance dosing from every 2-3 weeks to every 4-8 weeks depending on bodyweight. Here, we evaluated the efficacy and safety of ravulizumab in complement inhibitor-naïve children (under 18 years) with atypical hemolytic uremic syndrome. [...]
2021 - 10.1016/j.kint.2020.10.046
Kidney International, Vol. 100 Núm. 1 (july 2021) , p. 225-237  
Registre complet - Creative Commons
3.
10 p, 4.0 MB Eculizumab discontinuation in atypical haemolytic uraemic syndrome : TMA recurrence risk and renal outcomes / Ariceta Iraola, Gema (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Fakhouri, Fadi (CHU de Nantes) ; Sartz, Lisa (Skåne University Hospital (Suècia)) ; Miller, Benjamin (Alexion Pharmaceutical (Estats Units d'Amèrica)) ; Nikolaou, Vasilis (Parexel International (Regne Unit)) ; Cohen, David (Columbia University Medical Center) ; Siedlecki, Andrew M. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ; Ardissino, Gianluigi (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico) ; Universitat Autònoma de Barcelona
Eculizumab modifies the course of disease in patients with atypical haemolytic uraemic syndrome (aHUS), but data evaluating whether eculizumab discontinuation is safe are limited. Patients enrolled in the Global aHUS Registry who received ≥1 month of eculizumab before discontinuing, demonstrated haematologic or renal response prior to discontinuation and had ≥6 months of follow-up were analysed. [...]
2021 - 10.1093/ckj/sfab005
Clinical Kidney Journal, Vol. 14 (january 2021) , p. 2075-2084  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem